Intellectual Property Concerns and Domestic Bias Hold Back Research and Development in Asia-Pacific

Latest figures, released by MedTRACK, a biomedical database of Life Science Analytics, show stagnant product development across the Asia Pacific (APAC) region.

Latest figures, released by MedTRACK, a biomedical database of Life Science Analytics, show stagnant product development across the Asia Pacific (APAC) region. 

Only 15% of all drugs development is taking place in APAC, despite this region boasting some of the largest potential growth markets in the world. This compares to 28% in Europe and 55% in the US. 

Sarah Terry, President of MedTrack, comments: “Sluggish performance in the traditional major pharmaceutical markets is forcing Big Pharma to seek opportunities elsewhere. 

“The sheer magnitude of potential patient populations combined with a rapid economic growth and burgeoning middle classes make emerging APAC markets particularly attractive to foreign investors. However, issues and concerns regarding intellectual property and a lack of healthcare infrastructure in many of these markets mean that the region’s attractiveness as a location for drug development will remain low until